Pharmaceuticals company Shukra Pharmaceuticals announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: The company reported a revenue of Rs 2,352.23 lakh in Q1FY27, representing a significant YoY growth of 336.31% compared to Rs 539.11 lakh in Q1FY26. On a QoQ basis, revenue increased by 271.95% from Rs 632.41 lakh in Q4FY26. Total Income: Total income for the quarter stood at Rs 2,406.20 lakh, reflecting a YoY increase of 270.14% from Rs 650.08 lakh in Q1FY26 and a QoQ increase of 230.91% from Rs 727.13 lakh in Q4FY26. Profit Before Tax: The company recorded a profit before tax of Rs 1,817.18 lakh for Q1FY27, marking a massive increase compared to Rs 137.30 lakh in Q1FY26 and a significant jump from Rs 38.15 lakh in Q4FY26. Net Profit: Net profit for the period was reported at Rs 1,295.85 lakh in Q1FY27, a YoY growth of 1,158.59% compared to Rs 102.96 lakh in Q1FY26, and a substantial turnaround from a net loss of Rs 171.62 lakh in Q4FY26. Total Comprehensive Income: Total comprehensive income for Q1FY27 stood at Rs 1,295.85 lakh, compared to Rs 102.96 lakh in Q1FY26 and a comprehensive loss of Rs 180.34 lakh in Q4FY26. Earnings Per Share (EPS): Basic and Diluted EPS for Q1FY27 was Rs 0.30, compared to Rs 0.02 in Q1FY26 and Rs (0.04) in Q4FY26. Standalone Financial Highlights: Revenue from Operations: Standalone revenue for Q1FY27 was Rs 2,352.23 lakh, up 336.31% YoY from Rs 539.11 lakh in Q1FY26 and up 273.20% QoQ from Rs 630.29 lakh in Q4FY26. Total Income: Standalone total income stood at Rs 2,406.20 lakh in Q1FY27, compared to Rs 650.08 lakh in Q1FY26 and Rs 725.01 lakh in Q4FY26. Net Profit: Standalone net profit for the quarter was recorded at Rs 1,502.98 lakh in Q1FY27, marking a YoY growth of 1,359.77% from Rs 102.96 lakh in Q1FY26 and a recovery from a net loss of Rs 172.67 lakh in Q4FY26. EPS: Basic and Diluted standalone EPS for Q1FY27 stood at Rs 0.34, compared to Rs 0.02 in Q1FY26 and Rs (0.04) in Q4FY26. Business Highlights: Segment Performance: The company operates in two primary segments: Shukra Pharmaceutical and Shukra MedTech. Pharmaceutical Segment: During Q1FY27, this segment contributed the entire segment revenue of Rs 2,406.20 lakh and recorded a segment result (profit before tax and interest) of Rs 1,860.13 lakh. MedTech Segment: This segment, which became effective from October 1, 2025, did not report any revenue or profit for the quarter ended June 30, 2026. Consolidated Entities: The consolidated results include the performance of the holding company, Shukra Pharmaceuticals Limited, and its four subsidiaries: Shukra Diabetes Technologies Private Limited, Shukra Health Tech Private Limited, Shukra Robotics Private Limited, and Shukra Woundcare Private Limited. Investor Relations: The company reported receiving zero investor complaints during the quarter, with no complaints pending as of June 30, 2026. Equity Capital: The paid-up equity share capital of the company remained constant at Rs 4,378.79 lakh with a face value of Rs 1/- per equity share. Result PDF
Pharmaceuticals company Shukra Pharmaceuticals announced Q4FY26 & FY26 results Standalone Financial Highlights: Total Revenue from operations: For Q4FY26, revenue stood at Rs 630.29 lakh, representing a YoY decrease of 52.50% from Rs 1,326.98 lakh in Q4FY25 and a QoQ decrease of 83.89% compared to Rs 3,913.48 lakh in Q3FY26. For FY26, revenue reached Rs 5,670.61 lakh, representing a growth of 74.01% YoY from Rs 3,258.73 lakh in FY25. Total Income: For Q4FY26, total income was Rs 725.01 lakh, a YoY decrease of 50.80% from Rs 1,473.51 lakh and a QoQ decrease of 81.85% from Rs 3,995.01 lakh in Q3FY26. For FY26, total income reached Rs 6,129.10 lakh, up 66.58% YoY from Rs 3,679.39 lakh in FY25. Net Profit/Loss: The company reported a Net Loss of Rs 172.67 lakh in Q4FY26, compared to a Net Profit of Rs 538.64 lakh in Q4FY25 and a Net Profit of Rs 2,036.46 lakh in Q3FY26. For FY26, Net Profit stood at Rs 2,204.79 lakh, marking an increase of 130.26% YoY from Rs 957.51 lakh in FY25. Total Comprehensive Income: For FY26, the annual total comprehensive income was Rs 2,196.08 lakh compared to Rs 958.59 lakh in FY25. Earnings per share (Face Value Rs 1): Basic and Diluted EPS for FY26 stood at Rs 0.50 compared to Rs 0.22 in FY25. Consolidated Financial Highlights: Total Revenue from operations: For Q4FY26, revenue was Rs 632.41 lakh, reflecting a YoY decrease of 52.34% from Rs 1,326.98 lakh in Q4FY25 and a QoQ decrease of 83.84% from Rs 3,913.48 lakh in Q3FY26. For FY26, revenue reached Rs 5,672.74 lakh, a YoY growth of 85.46% from Rs 3,258.73 lakh in FY25. Total Income: For Q4FY26, total income stood at Rs 727.13 lakh, a YoY decrease of 50.65% from Rs 1,473.51 lakh and a QoQ decrease of 81.80% from Rs 3,995.01 lakh in Q3FY26. For FY26, total income was Rs 6,131.22 lakh, up 66.64% YoY from Rs 3,679.39 lakh in FY25. Net Profit/Loss: The Group reported a Net Loss of Rs 171.62 lakh in Q4FY26, compared to a Net Profit of Rs 538.64 lakh in Q4FY25 and a Net Profit of Rs 2,036.46 lakh in Q3FY26. For FY26, Net Profit was Rs 2,205.84 lakh, reflecting a YoY growth of 130.37% from Rs 957.51 lakh in FY25. Total Comprehensive Income: For FY26, the annual consolidated total comprehensive income reached Rs 2,197.13 lakh compared to Rs 958.59 lakh in FY25. Business Highlights Dividend: The Board recommended a Final Dividend of Rs 0.01 (1%) per equity share of face value Re 1 each fully paid for the financial year FY26. Preferential Allotment: The Board approved the allotment of 17,35,000 fully paid-up equity shares of face value Re 1 each to Dakshesh Shah and Parshva Texchem India Private Limited (Promoters), following the conversion of warrants at an issue price of Rs 34 per share. Equity Capital: Consequent to the allotment, the paid-up equity capital of the company increased to Rs 43,96,14,440 consisting of 43,96,14,440 equity shares of Re 1 each. Warrants Reconciliation: As of May 07, 2026, a total of 29,08,000 warrants remain outstanding for conversion out of the 46,43,000 warrants allotted on November 01, 2025. Segment-wise Performance (Consolidated FY26): Pharmaceutical Segment: Reported annual revenue of Rs 6,129.10 lakh and a segment profit of Rs 2,986.59 lakh before tax and interest. Medtech Segment: Reported annual revenue of Rs 0.00 and no separate segment profit for the year. The segment name "Shukra MedTech" became effective from October 1, 2025. Subsidiary Results: The consolidated results include the financial performance of four subsidiaries: Shukra Diabetes Technologies Private Limited, Shukra Health Tech Private Limited, Shukra Robotics Private Limited, and Shukra Woundcare Private Limited. Result PDF
Pharmaceuticals company Shukra Pharmaceuticals announced Q3FY26 results Revenue: Rs 3,913.48 lakh against Rs 1,058.43 lakh during Q3FY25, change 270%. PBT: Rs 2,683.15 lakh against Rs 409.48 lakh during Q3FY25, change 555%. PAT: Rs 2,036.46 lakh against Rs 316.44 lakh during Q3FY25, change 544%. EPS: Rs 0.47 for Q3FY26. Result PDF